Published on 08/12/2025

Change Control and E&L: Verification vs Re-Validation

In the pharmaceutical industry, ensuring the safety and efficacy of drug products is paramount. One critical aspect of this process revolves around managing extractables and leachables (E&L) associated with packaging and delivery systems. This tutorial provides a structured guide on implementing change control in the context of E&L, focusing on verification versus re-validation.

Understanding Extractables and Leachables (E&L)

Extractables and leachables refer to the chemical compounds that can migrate from packaging materials into pharmaceutical products. These substances can originate from various packaging components and may pose risks to drug safety and efficacy. Not only does the regulatory landscape demand robust E&L evaluations, but thorough assessments are also crucial for maintaining patient safety and product integrity.

First, it is essential to distinguish between extractables and leachables:

• Extractables: These are compounds that can be extracted from packaging materials using predefined solvents under specific conditions.
• Leachables: These are substances that migrate into the drug product during storage or in use, encompassing any cuts from the packaging due to temperature, time, and contact with the drug formulation.

A systematic E&L risk assessment must consider various factors, including the type of drug product, the formulation, and the packaging characteristics. The introduction of new packaging materials or any changes in processes necessitates rigorous analysis under the FDA guidelines on risk management.

Regulatory Guidance: E&L Practical Implementations

While managing E&L, it is vital to consider regulatory documents from the FDA, EMA, and other authorities globally that define acceptable limits rather than absolute thresholds for E&L. For instance, the EMA provides practical guidelines on specification criteria. Adopting a scientifically sound approach ensures compliance while safeguarding public health.

Key documentation contributing to E&L assessments includes the following regulatory expectations:

• FDA’s Process Validation Guidelines
• EU GMP Annex 1 concerning E&L
• QSIT for Risk Management as detailed in the PQRI guidelines

Integrating these guidelines into the development lifecycle of pharmaceuticals provides a robust framework for making informed decisions regarding the safety of device materials and packaging. E&L strategies must align with drug development timelines, and changes to the process or materials should trigger a reevaluation.

Change Control Process in E&L Management

The change control process is critical for ensuring ongoing product quality, especially in the case of extractables and leachables. A structured approach is necessary to clearly identify potential risks and validate the impact of any changes. Here’s a step-by-step guide:

Step 1: Document Current Processes and Systems

Before initiating any changes, compile detailed documentation of existing processes, analytical methodologies, and E&L data. This documentation serves as a benchmark against which changes can be validated.

Step 2: Identify and Assess Changes

Clearly define the nature of the proposed change. Changes to packaging materials, manufacturing processes, or suppliers can all influence the E&L profile. Conduct a risk assessment to evaluate how each change affects the current E&L profile:

• Consider the E&L profile of the new packaging material.
• Assess the potential for new extractables and leachables.
• Estimate the impact on patient safety and product efficacy.

Step 3: Implement Change Control Procedure

Once risks are assessed, initiate the formal change control procedure. This includes:

• Notifying relevant stakeholders about the planned change.
• Completing a change control form specifying the rationale behind the change.
• Filing the change in the appropriate quality management system (QMS).

Step 4: Verification of Impacts

Verification steps include new E&L testing based on the analytical evaluation threshold (AET) and dose-based threshold (DBT) calculations. Each component’s contribution to the overall E&L must be evaluated using robust analytical techniques such as LC-MS, GC-MS, and others.

Step 5: Re-Validation if Necessary

Re-validation is mandated when changes are significant enough to alter the E&L characteristics. This includes comprehensive stability and compatibility studies. The USP sets the standards for CCI testing, ensuring that the container closure system maintains its integrity under intended storage conditions.

Step 6: Review and Approval

Ensure that all findings from testing and evaluations are documented thoroughly and approved by the necessary quality assurance team. Final decisions should weigh both scientific evidence and compliance with current regulations as stipulated by bodies such as WHO, and regional authorities like EMA and FDA.

Analytical Evaluation Threshold (AET) and Dose-Based Threshold (DBT) Calculations

Two significant thresholds in the context of E&L are the AET and DBT, which play critical roles in evaluating the allowable amounts of leachables in pharmaceutical products.

Determining the Analytical Evaluation Threshold (AET)

AET is established based on the safety profile of the drug product and is calculated by considering the maximum allowable exposure incorporated with factors specific to the drug and patient population. Follow this methodology:

• Create a baseline risk assessment for each leachable component based on toxicological data.
• Factor in intended patient exposure to define the acceptable daily intake (ADI).
• Apply the safety factor defined by regulatory standards to determine the AET.

Calculating the Dose-Based Threshold (DBT)

The DBT is calculated primarily for products with higher risk potential, factoring in intended dosing regimens. Consider the following steps:

• Quantity of dosage forms to be administered over a specified timeframe.
• Potential frequency of exposure (acute vs. chronic).
• Application of safety margins based on toxicological profiles.

Defensible E&L Practices

Establishing defensible E&L practices is crucial for successful regulatory submissions, especially concerning new product launches or changes to existing products. To ensure robustness and compliance:

• Document all findings meticulously, creating a transparent audit trail.
• Engage third-party experts where necessary for objective evaluations.
• Regularly review and update the E&L risk management framework in alignment with regulatory changes.

Conclusion: Long-Term Impact of Change Control in E&L

Change control is an integral element in managing extractables and leachables within pharmaceutical packaging systems. A systematic approach ensures that any alterations are fully evaluated for their impact on product safety and efficacy. The successful implementation of this framework safeguards not only compliance with regulatory criteria but also the well-being of patients. By following robust E&L practices and adhering to guidelines set forth by regulatory entities such as the FDA and EMA, pharmaceutical professionals can assure quality and integrity throughout the lifecycle of their products.